CLTX CAR-T cell therapy for glioblastoma
No capital raise or buyback data
Historical delivery and spending consistency — data is limited for recently added companies.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| PHASE1/PHASE2 data readout — A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigopen_in_new Primary completion expected for NCT06055439. Indication: {"Neuroendocrine Tumors","Colorectal Cancer","Gastric Cancer"} | data readout | Speculative | removeMed | 1 May 2026 | Upcoming |
| CLTX CAR-T Phase 1 GBM safety data First-in-human safety data for chlorotoxin CAR-T in glioblastoma | data readout | Expected | arrow_upwardHigh | 31 July 2026 | Upcoming |
| PHASE1 data readout — CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastomaopen_in_new Primary completion expected for NCT05627323. Indication: {"Glioblastoma Multiforme of Brain"} | data readout | Speculative | removeMed | 1 Dec 2026 | Upcoming |
| Capital raise required Raised $8.4M (Dec 2025 placement $4.4M + $4.0M convertible note) | financing | Confirmed | arrow_upwardHigh | 23 Dec 2025 | Completed |